Clinical Trial Sponsors: Who Funds US Research
Who sponsors clinical trials, from pharmaceutical companies to universities and the NIH, and how sponsor type affects design, access and outcomes.
According to ClinicalTrials.gov, the NIH registry maintained by the National Library of Medicine contains more than 500,000 studies in more than 220 countries. The 2007 FDAAA requires registration for most FDA-regulated studies. See our methodology for source documents and refresh cadence.
The registry's biggest sponsors, by trial count
National Cancer Institute (NCI) sponsors the most trials in the registry, 3,257 in total with 326 currently recruiting, and federal and academic medical centers, not pharmaceutical companies, hold most of the top spots.
- 3,257
- National Cancer Institute (NCI) trials
- 2,844
- Mayo Clinic trials
- 2,692
- M.D. Anderson Cancer Center trials
- 2,032
- Massachusetts General Hospital trials
Sponsor names and counts are pulled live from the same ClinicalTrials.gov mirror used across this site.
Types of Clinical Trial Sponsors
Pharmaceutical and Biotech Companies
Industry sponsors the majority of clinical trials, investing billions annually in drug development. Major pharmaceutical companies (Pfizer, Johnson & Johnson, Roche, Novartis, Merck) maintain extensive trial portfolios spanning multiple therapeutic areas. Biotech companies often focus on specific conditions. Industry-sponsored trials are driven by the commercial pathway: the goal is to generate data sufficient for FDA approval and subsequent market access.
National Institutes of Health (NIH)
The NIH funds clinical research through its 27 institutes and centers. NIH-sponsored trials tend to focus on areas of public health importance that may not be commercially attractive, rare diseases, comparative effectiveness of existing treatments, public health interventions, and basic science questions. The NIH's clinical trial budget exceeds $3 billion annually.
Academic Medical Centers
Universities and teaching hospitals sponsor investigator-initiated trials. These are often smaller studies exploring novel approaches, testing off-label uses of approved drugs, or investigating conditions that lack commercial interest. Academic sponsors typically rely on NIH grants, foundation funding, or institutional resources. Academic trials contribute importantly to medical knowledge but may have limited budgets for enrollment.
Foundations and Nonprofits
Disease-specific foundations (American Cancer Society, Cystic Fibrosis Foundation, Michael J. Fox Foundation) fund clinical research directly or in partnership with academic institutions. These organizations bring patient advocacy perspectives to trial design and often fund research in areas underserved by industry.
Industry funds roughly 7 in 10 registered US clinical trials; the NIH is the largest non-commercial sponsor, and who pays can shape what a study chooses to measure.
How Sponsor Type Affects Trials
- Trial size: Industry trials tend to be larger with more sites. NIH and academic trials may be smaller but can address different questions.
- Speed of enrollment: Industry sponsors typically have more resources for recruitment. Academic trials may enroll more slowly.
- Publication: Industry sponsors control publication timing and may selectively report favorable results. Academic and NIH trials have more publication independence.
- Post-trial access: Industry sponsors may provide continued treatment access for participants after the trial ends. This varies by sponsor and is specified in the consent document.
- Cost to participants: Industry-sponsored trials typically cover all study-related costs. NIH and academic trials may cover fewer expenses.
The Changing Landscape of Trial Sponsorship
The clinical trial sponsorship landscape has shifted significantly over the past two decades. The share of industry-sponsored trials has grown as pharmaceutical companies invest more in late-stage development. Simultaneously, the biotech sector has expanded dramatically, small and mid-size biotech companies now initiate a significant portion of early-phase trials, often licensing promising compounds to larger pharmaceutical companies for Phase 3 development.
Contract research organizations (CROs) like IQVIA, Covance, and Parexel play an increasingly important role as intermediaries. While they do not technically "sponsor" trials, they manage much of the operational work, site selection, patient recruitment, data collection, and regulatory submissions, on behalf of the actual sponsor. The growth of CROs has enabled smaller sponsors to run complex multi-site trials that would otherwise be logistically infeasible.
Government-industry partnerships represent another growing model. Programs like BARDA (Biomedical Advanced Research and Development Authority) co-fund trials for products addressing national security threats (biodefense, pandemic preparedness). The NIH's NCATS (National Center for Advancing Translational Sciences) works to accelerate the translation of basic research into clinical applications, often through public-private partnerships.
Reading Sponsor Profiles on PlainTrial
Each sponsor on PlainTrial has a profile page showing their complete trial portfolio: total trials, recruiting trials, phase distribution, and the conditions they study. This allows you to understand an organization's research focus and track record. Large pharmaceutical sponsors may have hundreds of trials spanning oncology, immunology, neuroscience, and cardiovascular disease. Academic sponsors typically have portfolios concentrated in their areas of research specialization.
Reading the sponsor list
A large sponsor portfolio signals institutional research infrastructure, not a guarantee that a specific trial is a fit for you.
- Open a sponsor's full profile before you rely on a single trial listing, it shows their complete recruiting history and phase mix. Browse all sponsors
- Academic and NIH-affiliated sponsors dominate this list, they run investigator-initiated as well as industry-partnered studies. How trials are designed
- Cross-check a sponsor against the condition you care about; a top-10 sponsor overall may have few trials in your specific area. Browse the conditions directory
Trial-count rank reflects portfolio size, not trial quality, funding source, or your personal eligibility for any listed study.
Frequently Asked Questions
Who pays for clinical trials?
Clinical trials are funded by pharmaceutical and biotech companies (industry-sponsored), the National Institutes of Health (NIH) and other federal agencies, universities and academic medical centers, and charitable organizations. Industry sponsors the majority of clinical trials in the US, roughly 70% of all registered trials have industry funding. The NIH is the largest non-industry funder.
Does the sponsor affect the trial quality?
All clinical trials must meet the same regulatory standards regardless of sponsor. However, sponsor type can influence study design, endpoint selection, publication practices, and post-trial access to treatment. Industry-sponsored trials have been criticized for favorable endpoint selection and publication bias, though regulatory requirements have improved transparency. NIH-sponsored trials are generally considered to have fewer conflicts of interest but may have smaller budgets and slower enrollment.
Can I see who sponsors a trial before enrolling?
Yes. ClinicalTrials.gov requires disclosure of the trial sponsor and collaborators. PlainTrial displays this information on every trial detail page and provides sponsor profile pages showing each organization's full trial portfolio. The informed consent document must also identify who is funding the research.